

FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED)		ATTORNEY'S DOCKET NUMBER G-1344	
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>10/031122</b>	
INTERNATIONAL APPLICATION NO. <b>PCT/GB00/02361</b>	INTERNATIONAL FILING DATE <b>06/15/2000 (06.15.00)</b>	PRIORITY DATE CLAIMED <b>07/13/1999 (07.13.99)</b>	
TITLE OF INVENTION: SULFONAMIDE SUBSTITUTED BENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICAMENTS			
APPLICANT(S) FOR DO/EO/US: Sandra Ginette Milutinovic, et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
1.	<input checked="" type="checkbox"/>	This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.	
2.	<input type="checkbox"/>	This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.	
3.	<input type="checkbox"/>	This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).	
4.	<input checked="" type="checkbox"/>	A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.	
5.	<input checked="" type="checkbox"/>	A copy of the International Application as filed (35 U.S.C. 371(c)(2))	
	<input type="checkbox"/>	a. is transmitted herewith (required only if not transmitted by the International Bureau).	
	<input type="checkbox"/>	b. has been transmitted by the International Bureau.	
	<input checked="" type="checkbox"/>	c. is not required, as the application was filed in the United States Receiving Office (RO/US).	
6.	<input type="checkbox"/>	A translation of the International Application into English (35 U.S.C. 371(c)(2)).	
	<input checked="" type="checkbox"/>	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))	
	<input type="checkbox"/>	a. are transmitted herewith (required only if not transmitted by the International Bureau).	
	<input type="checkbox"/>	b. have been transmitted by the International Bureau.	
	<input type="checkbox"/>	c. have not been made; however, the time limit for making such amendments has NOT expired.	
	<input checked="" type="checkbox"/>	d. have not been made and will not be made.	
8.	<input type="checkbox"/>	A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
9.	<input checked="" type="checkbox"/>	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).	
10.	<input checked="" type="checkbox"/>	A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)).	
<b>Items 11. to 16. below concern document(s) or information included:</b>			
11.	<input type="checkbox"/>	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.	
12.	<input checked="" type="checkbox"/>	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.	
13.	<input type="checkbox"/>	A FIRST preliminary amendment.	
	<input type="checkbox"/>	A SECOND or SUBSEQUENT preliminary amendment.	
14.	<input type="checkbox"/>	A substitute specification.	
15.	<input type="checkbox"/>	A change of power of attorney and/or address letter.	
16.	<input type="checkbox"/>	Other items or information:	

10/031122

PCT/GB00/02361

ATTORNEY'S DOCKET NUMBER

G-1344

17. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO. **\$1040.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but International Search Report prepared by the EPO or JPO ..... **\$890.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... **\$750.00**

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... **\$710.00**

International preliminary examination fee paid to USPTO (37 CFR  
1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... **\$100.00**

CALCULATIONS PTO USE ONLY

**ENTER APPROPRIATE BASIC FEE AMOUNT =** \$ 890.00

Surcharge of **\$130.00** for furnishing the oath or declaration later than 20 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	27 - 20 =	7	X \$18.00
Independent claims	2 - 3 =		X \$84.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable)	+ \$280.00	\$ 280.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$

Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity  
Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

**SUBTOTAL =** \$ 1296.00

Processing fee of **\$130.00** for furnishing English translation later than 20 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

**TOTAL NATIONAL FEE =** \$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).

**\$40.00 per property****TOTAL FEES ENCLOSED =** \$ 1296.00

Amount to be refunded	\$
charged	\$

a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.b. ☒ Please charge my Deposit Account No. 05-0840 in the amount of \$ 1296.00 to cover the above fees. A duplicate copy of this sheet is enclosed.c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 05-0840. A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive  
(37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

ELI LILLY AND COMPANY  
PATENT DIVISION/JAG  
LILLY CORPORATE CENTER

*Janet A. Gongola*  
SIGNATURE  
Janet A. Gongola  
NAME

Date

48,436  
REGISTRATION NUMBER

(317) 277-6186  
TELEPHONE NUMBER

## SULFONAMIDE SUBSTITUTED BENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICAMENTS


This invention relates to novel chemical compounds and their use as pharmaceuticals.

5

It is well known that chemical compounds which modulate the activity of neuronal calcium channels are potentially useful in treating disorders of the central nervous system.

10

The compounds of the invention have the following general formula:



(I)

15

in which the aminosulfonyl group is attached at the 3-  
or 4-position, and in which

R<sup>1</sup> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub>  
5 cycloalkyl-C<sub>1-4</sub> alkyl or optionally substituted phenyl-  
C<sub>1-4</sub> alkyl,

R<sup>2</sup> is C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-  
C<sub>1-4</sub> alkyl, optionally substituted phenyl-C<sub>1-4</sub> alkyl or  
10 -(CH<sub>2</sub>)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> where R<sup>5</sup> and R<sup>6</sup> are each hydrogen or C<sub>1-6</sub>  
alkyl, and

R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub>  
cycloalkyl-C<sub>1-4</sub> alkyl, C<sub>3-6</sub> alkenyl, optionally  
15 substituted phenyl or optionally substituted phenyl-C<sub>1-4</sub>  
alkyl,

or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup>, or R<sup>5</sup> and R<sup>6</sup>, together with  
the nitrogen atom to which they are attached, form a  
20 carbocyclic group containing 4 to 7 carbon atoms  
optionally substituted with one to three methyl or ethyl  
groups and optionally containing an oxygen atom or a  
further nitrogen atom, said carbocyclic group being

optionally fused to an optionally substituted phenyl group;

or a salt thereof.

5

The compounds of the invention have been found to be active in tests that show modulation of voltage-dependent calcium channels, and are thus indicated for use in the treatment of diseases in which such

10 modulation is beneficial, in particular disorders of the central nervous system.

Thus, the invention includes a method of treating a disorder of the central nervous system, which comprises

15 administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof.

The invention also includes the use of a compound of

20 formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disorder of the central nervous system.

The invention also includes the use of a compound of

25 formula (I), or a pharmaceutically acceptable salt

thereof, in the manufacture of a medicament for treating a disorder of the central nervous system.

In the above formula (I), a C<sub>1-6</sub> alkyl group includes

- 5 methyl, ethyl, propyl, isopropyl, butyl, tert. butyl and hexyl, and is preferably methyl or ethyl. A substituted phenyl group is phenyl substituted with one or more, for example one to three, substituents selected from, for example C<sub>1-4</sub> alkyl, especially methyl, C<sub>1-4</sub> alkoxy,
- 10 especially methoxy and ethoxy, hydroxy, nitro, cyano, halo, especially chloro or fluoro, trihalomethyl, especially trifluoromethyl, carboxy and C<sub>1-4</sub> alkoxy-carbonyl. A halo atom is preferably chlorine, bromine or fluorine. A substituted phenyl group preferably has
- 15 one to three substituents selected from hydroxy, C<sub>1-4</sub> alkyl, halo, nitro and trifluoromethyl. An optionally substituted phenyl-C<sub>1-4</sub> alkyl group is preferably of the formula R-(CH<sub>2</sub>)<sub>n</sub>- where R is optionally substituted phenyl and n is 1 to 4, but the linking chain can also
- 20 be branched alkylene. A C<sub>3-10</sub> cycloalkyl group is preferably, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl and these groups may optionally be substituted by one or two C<sub>1-4</sub> alkyl, especially methyl, substituents. A C<sub>3-10</sub> cycloalkyl-
- 25 C<sub>1-4</sub> alkyl group is one such cycloalkyl group attached

to a C<sub>1-4</sub> alkyl, and is preferably of the formula  
R-(CH<sub>2</sub>)<sub>n</sub>- where R is cycloalkyl and n is 1 to 4. When  
R<sup>3</sup> or R<sup>4</sup> is C<sub>1-6</sub> alkyl it is preferably C<sub>3-6</sub> alkyl.

- 5 The groups R<sup>1</sup> and R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, and R<sup>5</sup> and R<sup>6</sup>, can form  
a carbocyclic ring with the nitrogen to which they are  
attached and optionally also contain an oxygen atom or  
an additional nitrogen. Preferred examples, including  
the nitrogen of the amino sulfonyl group, are  
10 pyrrolidino, piperazino, morpholino and especially  
3,5-dimethylpiperidino.

- A particular group of compounds of the invention is one  
of formula (I) in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub>  
15 alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl or  
optionally substituted phenyl-C<sub>1-4</sub> alkyl, and R<sup>1</sup> can in  
addition be hydrogen, or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup>  
together with the nitrogen atom to which they are  
attached, form a carbocyclic group as defined above.

20

In a preferred group of compounds R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are  
each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub>  
alkyl or optionally substituted phenyl-C<sub>1-4</sub> alkyl, and  
R<sup>1</sup> is in addition hydrogen.

10034122.010902

It is preferred that  $R^1$  is hydrogen. Furthermore,  $R^3$  and  $R^4$ , which can be the same or different, are preferably  $C_{1-4}$  alkyl. It is further preferred that  $R^2$  is optionally substituted phenyl- $C_{1-4}$  alkyl.

A further preferred group of compounds is one of formula (I) in which  $R^2$  is  $-(CH_2)_2NR^5R^6$ .

10 A further preferred group of compounds is one of formula (I) in which  $R^3$  or  $R^4$  is  $C_{3-6}$  alkyl or when  $R^3$  and  $R^4$  are taken together with the nitrogen atom they form a piperidine ring which is substituted at the 3- and/or 5-positions with one or two methyl or ethyl substituents.

It will be appreciated that the compounds of the invention can contain one or more asymmetric carbon atom which gives rise to enantiomers. The compounds can be prepared as racemates or can be made from enantiomeric intermediates. Both racemates and enantiomers form part of the present invention.

It will also be understood that salts of the compounds of the invention can be prepared and such salts are



included in the invention. They can be any of the well known acid addition salts. Acid addition salts are preferably the pharmaceutically acceptable non-toxic addition salts with suitable acids, such as those with

- 5 inorganic acids, for example hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example glycollic, maleic, fumaric, malic, oxalic, tartaric, citric, salicylic or o-acetoxybenzoic acids, or organic
- 10 sulfonic acids, methane sulfonic, 2-hydroxyethane sulfonic, toluene-p-sulfonic or naphthalene-2-sulfonic acids.


- In addition to pharmaceutically-acceptable salts, other
- 15 salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically-acceptable, salts, or are useful for identification, characterisation or purification.

20

The invention includes a process for producing the compounds of formula (I) above which comprises reducing a compound of the formula:

1003112.010902

- 8 -




(II)

The reaction is preferably carried out in an organic solvent, for example, at a temperature of 0° C. to

5 100° C., employing a reducing agent, for example lithium aluminium hydride.

Compounds of formula (II) can readily be prepared by conventional methods, for example, by reacting a

10 compound of the formula:



(III)


where X is a leaving group such as, for example, halo or hydroxy, with an amine of the formula HNR<sup>1</sup>R<sup>2</sup>.

The reaction is preferably carried out in an organic solvent such as, for example, chloroform or acetonitrile, at a temperature of from 0° C. to 100° C. such as, for example, ambient temperature.

Intermediate compounds of formula (III) are known in the art and can be readily prepared by known methods. When an acid halide is employed (X is halo such as, for example, chloro), the reaction is preferably carried out in the presence of a solid phase scavenger to absorb the acid liberated by the reaction. When the free acid is employed (X is hydroxy), a condensing reagent such as,

for example, dimethylaminopropyl-ethylcarbodiimide can be employed.

A further route to the compounds of the invention, which is also included in the invention, involves the reduction of the imine corresponding to the compound of formula (III):



10

employing a reducing agent as, for example, sodium borohydride. Compounds of formula (IV) can readily be prepared by reacting an amine of formula R<sup>1</sup>R<sup>2</sup>NH with the appropriate benzaldehyde derivative, which can, in its turn, be prepared by reducing the corresponding benzoic

15

acid derivative to the alcohol, followed by oxidation to the required benzaldehyde intermediate.

Amine reactants of the formula  $\text{HNR}^1\text{R}^2$  are well known and  
5 can be readily prepared by known methods. Those in which  $\text{R}^2$  is  $-(\text{CH}_2)_2\text{NR}^5\text{R}^6$  can, for example, be prepared by reductive amination, that is, by reacting the appropriate diamine with an aldehyde in reducing conditions.

10

Alternatively, compounds of formula (I) in which  $\text{R}^2$  is  $-(\text{CH}_2)_2\text{NR}^5\text{R}^6$  can be prepared by alkylation of the corresponding compound of formula (I) in which  $\text{R}^1$  is hydrogen.

15

As mentioned above, the compounds of the invention are active in tests that indicate their utility in the treatment of diseases of the central nervous system.

20

The compounds modulate the activity of calcium channels and, in particular, they block voltage sensitive calcium channels as determined in a test based on Boot J. R., et al., Specificity of autoantibodies in the Lambert-Eaton Myasthenic Syndrome, Ann NY Acad. Sci. (1997), in

25

which measurements of calcium flux using calcium

sensitive dyes are made. Compounds described in the following Examples were found to inhibit voltage-dependent calcium channels in cloned human cell lines expressing specific voltage-dependent calcium channels

5 with an IC<sub>50</sub> of less than 10  $\mu$ M.

The compounds of the invention are thus indicated for use in the treatment of anoxia, ischaemia, stroke and heart failure, migraine, diabetes, cognitive impairment,

10 pain, epilepsy, traumatic head or spinal injury, AIDS related dementia and blindness, amnesia, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's diseases and age-related memory disorders, Down's syndrome, mood disorders, drug

15 or alcohol addition withdrawal, nausea from chemotherapy, and carbon monoxide or cyanide poisoning.

The invention also includes a pharmaceutical composition comprising a pharmaceutically acceptable diluent or

20 carrier in association with the compound of the invention or a pharmaceutically acceptable salt or ester thereof.

The compound may be administered by various routes, for example by the oral or rectal route, topically or

25 parenterally, for example by injection or infusion,

being usually employed in the form of a pharmaceutical composition. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound. In making the compositions

- 5 of the present invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, and/or enclosed within a carrier which may, for example, be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent,
- 10 it may be a solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, ointments containing, for example, up to
- 15 10% by weight of the compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.

- Some examples of suitable carriers are lactose,
- 20 dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydrobenzoate, talc magnesium stearate and mineral oil. The compositions of the injection may, as is well known
- 25 in the art, be formulated so as to provide quick,

sustained or delayed release of the active ingredient after administration to the patient.

Where the compositions are formulated in unit dosage form, it is preferred that each unit dosage form contains from 5 mg to 500 mg. The term 'unit dosage form' refers to physically discrete units suitable as unit dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.

The active compound is effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.5 to 300 mg/kg, more usually in the range of from 5 to 100 mg/kg. However, it will be understood that the amount administered will be determined by the physician in the light of the relevant circumstances including the conditions to be treated, the choice of compound to be administered and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.

The invention is illustrated by the following Preparations and Examples.

1003732.010902



EXAMPLE 1

## 5 4-[(N,N-di-n-propylamino)sulfonyl]-benzoic acid

To a stirred solution of di-n-propylamine (3.03 g, 0.03 mole) in dry tetrahydrofuran (20 ml) at 0° C. (ice/salt bath), was added 4-chlorosulfonylbenzoic acid (2.2 g, 0.01 mole). Stirring was continued for 1 hour. Ice water was added cautiously and the reaction made acid with 2NHCl. The 4-[(N,N-di-n-propylamino)sulfonyl]-benzoic acid was collected by filtration as a white solid which was dried in vacuo at 40° C.

EXAMPLE 2

## 20 4-[(N-di-n-propylamino)sulfonyl]-N-4-methoxybenzyl-benzamide

To a solution of 4-[(N,N-di-n-propylamino)sulfonyl]-benzoic acid (2.85 g, 0.01 mole) in dry dichloromethane (ml) at 0° C. was added oxalyl chloride (2.54 g, 0.02 mole) and dimethylformamide (4 drops). The

reaction mixture was stirred for 2 hours. The reaction was evaporated to dryness *in vacuo*. The resulting acid chloride was added to a stirred solution of *p*-methoxybenzylamine (1.51 g, 0.011 mole) and triethylamine (1.11 g, 0.011 mole) in dry tetrahydrofuran (25 ml) at 0-5° C. After stirring for 4 hours the reaction was poured into ice water and extracted with ethyl acetate. The solvent was washed with brine, dried and evaporated to dryness *in vacuo*.

Chromatography on flash silica using 10% ethyl acetate/dichloromethane gave 4-[(N,N-di-n-propylamino)sulfonyl]-N-4-methoxybenzyl-benzamide as a white solid. M.p. 132-134° C.

### EXAMPLE 3

*N,N*-di-*n*-propyl-4-[(4-methoxybenzyl)amino]methyl benzenesulfonamide

To a stirred solution of 4-[(N,N-di-*n*-propylamino)sulfonyl]-N-4-methoxybenzyl-benzamide (1.87g, 4.62mmole) in dry ether (50ml) was added a solution of 2M lithium aluminium hydride in tetrahydrofuran (4.63ml, 9.24mmole). The reaction was heated at reflux for 2 hours. After cooling to room temperature water (1ml)

was added dropwise with caution followed by 2NNaOH (1ml). When gas evolution ceased the reaction mixture was filtered through a pad of celite which was well washed with ether. After removal of the solvent *in-*  
5 *vacuo* the product was purified by chromatography on flash silica eluting with 10% methanol/ethyl acetate. The resulting amine was converted to the maleic acid salt and re-crystallised from ethanol/ether to give *N,N*-di-*n*-propyl-4-{{(4-methoxybenzyl)amino)methyl} benzenesulfonamide maleate. mp. 133-135°C  
10

Similarly prepared were:

*N,N*-di-*n*-propyl-3-{{(4-methoxybenzyl)amino)methyl}

15 benzenesulfonamide maleate. mp. 160-162°C

*N,N*-di-*n*-propyl-4-{{(3,4-dimethoxyphenethyl)

amino)methyl}benzenesulfonamide maleate. mp. 130-132°C

*N*-(3,3-dimethylpiperidino)-3-{{(4-fluorobenzyl)

amino)methyl}benzenesulfonamide maleate. mp. 169-171°C

20 *N*-(3,3-dimethylpiperidino)-4-{{(4-fluorobenzyl)

amino)methyl}benzenesulfonamide maleate. mp. 196-198°C

*N,N*-di-*n*-propyl-3-{{(4-fluorobenzyl)amino)methyl}

benzenesulfonamide maleate. mp. 168-170°C

*N*-phenyl-*N*-*n*-propyl-4-{{dimethylamino)methyl}

25 benzenesulfonamide maleate. mp. 154-156°C

*N*-(3,3-dimethylpiperidino)-3-([(4-fluorobenzyl)-*N*-methylamino]methyl)benzenesulfonamide maleate. Mass spectrum:  $MH^+ = 405$  (TSP+)

5 *N*-(3,3-dimethylpiperidino)-3-([(4-fluorobenzyl)-*N*-benzylamino]methyl)benzenesulfonamide maleate. mp. 183-185°C

*N*-phenyl-*N*-methyl-3-([(4-fluorobenzyl)amino]methyl)benzenesulfonamide maleate. mp. 194-196°C

10 *N*-phenyl-*N*-*n*-butyl-4-([hexylamino]methyl)benzenesulfonamide maleate. mp. 106-108°C

*N*-(3-ethylpiperidino)-3-([(4-fluorobenzyl)amino]methyl)benzenesulfonamide maleate. mp. 140-142°C

15 *N*-(3,3-dimethylpiperidino)-3-([(cyclohexylmethyl)amino]methyl)benzenesulfonamide hydrochloride. mp. 147-149°C

*N*-(3-methylpiperidino)-4-([(4-chlorophenethyl)amino]methyl)benzenesulfonamide maleate. mp. 176-178°C

20 *N*-(3-methylpiperidino)-4-([(4-chlorophenethyl)-*N*-methylamino]methyl)benzenesulfonamide maleate. mp. 168-170°C

3-([2-(dimethylamino)ethyl](4-fluorobenzyl)amino]methyl)-*N*-3,3-dimethylpiperidino-benzenesulfonamide maleate as an oil. Mass spectrum( $MH^+ = 462$  (10%)) (TSP+)

25 3-([2-(dimethylamino)ethyl](cyclohexylmethyl)

amino]methyl}-N-3,3-dimethylpiperidino-  
benzenesulfonamide maleate. mp. 149-151°C

5 EXAMPLE 4

4-([2-(piperidino)ethyl](2-[3,4-  
dimethoxy]phenylethyl)amino]methyl)-N,N-di-n-  
propylbenzene sulfonamide dihydrochloride

10

To solution of N,N-di-n-propyl-4-([3,4-  
dimethoxyphenethyl)amino]methyl)benzene sulfonamide (550  
mg, 1mmole) in dry acetonitrile (100ml) was added sodium  
carbonate ( 440mg, 4.4mmole), potassium iodide (166mg,  
15 1mmole) and 2-chloroethylpiperidine hydrochloride  
(184mg, 1mmole). The reaction was stirred and heated at  
reflux for 18 hours. The reaction was poured into ice  
water and extracted with ethyl acetate, washed with  
brine, dried and evaporated to dryness *in-vacuo*.

20

Chromatography on flash silica by elution with  
10%methanol/dichloromethane gave 4-([2-  
(piperidino)ethyl](2-[3,4-dimethoxy]phenylethyl)amino]  
methyl)-N,N-di-n-propylbenzenesulfonamide which was  
crystallised as its dihydrochloride salt. mp. 135-137°C

25

EXAMPLE 5

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(4-methylbenzyl)amine

5

A mixture of a 0.15 M solution of 3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzaldehyde in methanol (0.25 ml) and a 0.1 M solution of 4-methylbenzylamine in methanol (0.25 ml) was stirred at room temperature for 1

10 hour. A 0.15 M solution of sodium borohydride in methanol (0.25 ml) was added and stirring continued for a further 16 hours. The mixture was then applied to a methanol-washed 500 mg SCX solid phase extraction (SPE) cartridge and washed through with methanol (2.5 ml).

15 The cartridge was then eluted with a 2 M solution of ammonia in methanol (2.5 ml). The eluate was vacuum evaporated to give the required product. (TS-MS:  $m/z$  387,  $[M+H]^+$ ).

20 The following compounds were similarly prepared (mass spectrum values are given in brackets).

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-[3-(4-methylpiperazin-1-yl)propyl]amine (423)

25

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(3-morpholin-4-ylpropyl)amine (410)

*N*-(4-chlorobenzyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (407/408)

*N*-(cyclohexylmethyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (379)

10 *N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-{3-(1*H*-imidazol-1-yl)propyl}amine (391)

*N*-butyl-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (339)

15 *N*-(*tert*-butyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (339)

*N*-(2-chlorobenzyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (407/408)

*N*-(4-chlorophenethyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (421/422)

10037725.016001

*N*-(2-chlorophenethyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (421/422)

*N*-(2,4-dichlorobenzyl)-*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amine (442)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-isopentylamine (353)

10 *N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(3-methoxypropyl)amine (355)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(2-methylbenzyl)amine (387)

15 *N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(3-methylcyclohexyl)amine (379)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-hexylamine (367)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-propylamine (325)

25 *N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(4-methylphenethyl)amine (401)



*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-[3-(trifluoromethyl)benzyl]amine (441)

- 5 *N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-[3-(trifluoromethyl)phenethyl]amine (455)

EXAMPLE 6

- 10 1-({3-[(4-benzylpiperidin-1-yl)methyl]phenyl}sulfonyl)-3,3-dimethylpiperidine

A mixture of a 0.15 M solution of 3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzaldehyde in  
15 dichloromethane (0.25 ml), a 0.1 M solution of 4-benzylpiperidine in dichloromethane (0.25 ml) and a 0.15 M solution of sodium tri-acetoxyborohydride in dichloromethane (0.25 ml) was stirred at room temperature for 22 hours. Methanol (1 ml) was added and  
20 the mixture applied to a methanol-washed 500 mg SCX solid phase extraction (SPE) cartridge and washed through with methanol (2.5 ml). The cartridge was then eluted with a 2 M solution of ammonia in methanol (2.5 ml). The eluate was vacuum evaporated to give the  
25 required product. (TS-MS: m/z 441, [M+H]<sup>+</sup>).

The following compounds were similarly prepared (mass spectrum values are given in brackets).

- 2-(butyl{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amino)ethan-1-ol (383)
- 2-(benzyl{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}amino)ethan-1-ol (417)
- 10 N-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-N,N-bis(2-methoxyethyl)amine (399)
- 1-(3,4-dichlorophenyl)-4-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}piperazine (497)
- 15 N-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-N-ethyl-N-(pyridin-4-ylmethyl)amine (402)
- 1-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-4-(4-fluorophenyl)piperazine (446)
- 20 4-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}piperazine-1-carbaldehyde (380)
- 25 4-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}morpholine (353)

1-[4-(4-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}piperazin-1-yl)phenyl]ethan-1-one  
(470)

5

3,3-dimethyl-1-{[3-(pyrrolidin-1-ylmethyl)phenyl)sulfonyl]piperidine (337)

10

2-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-  
1,2,3,4-tetrahydroisoquinoline (399)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N,N*-  
dipropylamine (367)

15

1-benzhydryl-4-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}piperazine (518)

*N*-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}-*N*-(2-methoxyethyl)-*N*-propylamine (383)

20

EXAMPLE 7

1-{3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzyl}piperidine-4-carboxamide

25

A mixture of a 0.15 M solution of 3-[(3,3-dimethylpiperidin-1-yl)sulfonyl]benzaldehyde in methanol (0.25 ml), a 0.1 M solution of piperidine-4-carboxamide in methanol/acetic acid 4:1 v/v (0.25 ml) and a 0.15 M solution of sodium cyanoborohydride in methanol (0.25 ml) was stirred at room temperature for 18 hours. The mixture applied to a methanol-washed 500 mg SCX solid phase extraction (SPE) cartridge and washed through with methanol (2.5 ml). The cartridge was then eluted with a 2 M solution of ammonia in methanol (2.5 ml) and the eluate vacuum evaporated. The residue was dissolved in chloroform (2 ml) and the solution added to isocyanatomethyl-polystyrene (loading 1 mmole/g, 100 mg). The suspension was shaken at room temperature for 16 hours, then filtered. The resin was washed with chloroform (2 x 2 ml) and the combined filtrates vacuum evaporated to give the required product. (TS-MS: m/z 394, [M+H]<sup>+</sup>).

The following Examples illustrate typical formulations containing a compound of the invention.

EXAMPLE 8

Tablets each containing 10 mg of active ingredient are made up as follows:

	Active ingredient	10 mg
5	Starch	160 mg
	Microcrystalline cellulose	100 mg
	Polyvinylpyrrolidone (as 10% solution in water)	13 mg
	Sodium carboxymethyl starch	14 mg
	Magnesium stearate	3 mg
10		_____
	Total	300 mg
		_____

The active ingredient, starch and cellulose are mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders and passed through a sieve. The granules so produced are dried and re-passed through a sieve. The sodium carboxymethyl starch and magnesium stearate are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 300 mg.

#### EXAMPLE 9

Capsules each containing 20 mg of active ingredient are made as follows:

	Active ingredient	20 mg
	Dried starch	178 mg
	Magnesium stearate	2 mg
5		_____
	Total	200 mg
		_____

10 The active ingredient, starch and magnesium stearate are  
passed through a sieve and filled into hard gelatine  
capsules in 200 mg quantities.

EXAMPLE 10

15 Capsules each containing 20 mg of medicament are made as  
follows:

	Active ingredient	20 mg
20	Lactose	171 mg
	Sodium lauryl sulphate	2 mg
	Sodium starch glycollate	6 mg
	Magnesium stearate	1 mg
25		_____
		200 mg
		_____

The active ingredient, lactose, sodium lauryl sulphate and sodium starch glycollate are mixed thoroughly. The blend is mixed with the magnesium stearate and filled into hard gelatine capsules in 200 mg quantities.

#### EXAMPLE 11

Tablets each containing 20 mg and medicaments are made as follows:

	Active ingredient	20 mg
	Lactose	103 mg
	Microcrystalline cellulose	150 mg
15	Hydroxypropylmethylcellulose	15 mg
	Sodium starch glycollate	9 mg
	Magnesium stearate	3 mg
		<hr/>
		300 mg
20		<hr/>

The active ingredient, lactose, microcrystalline cellulose, sodium starch glycollate and hydroxypropylmethylcellulose are passed through a sieve and blended together. Water is added to the blended powders to form a damp mass. The damp mass is passed

- 30 -


through a coarse screen, dried, then re-screened. The dried granules are mixed with the magnesium stearate and compressed into tablets of 300 mg weight.

1303112.010902



CLAIMS

1. A compound of the formula



(II)

in which the aminosulfonyl group is attached at the 3- or 4-position, and in which

R<sup>1</sup> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl or optionally substituted phenyl-C<sub>1-4</sub> alkyl,

R<sup>2</sup> is C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, optionally substituted

phenyl-C<sub>1-4</sub> alkyl or -(CH<sub>2</sub>)<sub>2</sub>NR<sup>5</sup>R<sup>6</sup> where R<sup>5</sup> and R<sup>6</sup> are each hydrogen or C<sub>1-6</sub> alkyl, and

- 5 R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl, C<sub>3-6</sub> alkenyl, optionally substituted phenyl or optionally substituted phenyl-C<sub>1-4</sub> alkyl,
- 10 or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup>, or R<sup>5</sup> and R<sup>6</sup>, together with the nitrogen atom to which they are attached, form a carbocyclic group containing 4 to 7 carbon atoms optionally substituted with one to three methyl or ethyl groups and optionally containing an
- 15 carbocyclic group being optionally fused to an optionally substituted phenyl group;
- or a salt thereof.

- 20 2. A compound according to Claim 1 in which R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> are each C<sub>1-6</sub> alkyl, C<sub>3-10</sub> cycloalkyl, C<sub>3-10</sub> cycloalkyl-C<sub>1-4</sub> alkyl or optionally substituted phenyl-C<sub>1-4</sub> alkyl, and R<sup>1</sup> can in addition be hydrogen, or R<sup>1</sup> and R<sup>2</sup>, or R<sup>3</sup> and R<sup>4</sup> together with

the nitrogen atom to which they are attached, form a carbocyclic group.

3. A compound according to Claim 2 in which  $R^1$ ,  $R^2$ ,  $R^3$  and  $R^4$  are each  $C_{1-6}$  alkyl,  $C_{3-10}$  cycloalkyl,  $C_{3-10}$  cycloalkyl- $C_{1-4}$  alkyl or optionally substituted phenyl- $C_{1-4}$  alkyl, and  $R^1$  can in addition be hydrogen.
4. A compound according to Claim 3 in which  $R^1$  is hydrogen,  $R^2$  is optionally substituted phenyl- $C_{1-4}$  alkyl and  $R^3$  and  $R^4$  are  $C_{1-6}$  alkyl.
5. A compound according to Claim 1 in which  $R^2$  is  $-(CH_2)_2NR^5R^6$ .
6. A compound according to Claim 1 or 5 in which  $R^3$  or  $R^4$  is  $C_{3-6}$  alkyl or when  $R^3$  and  $R^4$  are taken together with the nitrogen atom they form a piperidine ring which is substituted at the 3- and/or 5-positions with one or two methyl or ethyl substituents.

7. A pharmaceutical formulation comprising a compound according to any of Claims 1 to 6 or a pharmaceutically acceptable salt thereof, together with a diluent or carrier therefor.
- 5
8. A compound according to any of Claims 1 to 6, for use as a pharmaceutical.
9. Use of a compound according to any of Claims 1 to 6, in the manufacture of a medicament for treating a disorder of the central nervous system.
- 10
10. A method of treating a disorder of the central nervous system which comprises administering an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.
- 15

**DECLARATION FOR  
UTILITY OR DESIGN  
PATENT APPLICATION**

<b>Attorney Docket Number</b>	<b>G-1344</b>
<b>First Named Inventor</b>	<b>Milutinovic, et al.</b>
<b>COMPLETE IF KNOWN</b>	
<b>Application Number</b>	
<b>Filing Date</b>	
<b>Group Art Unit</b>	
<b>Examiner Name</b>	

☒

Declaration Submitted with Initial Filing

☐

Declaration Submitted after Initial Filing

**As a below named inventor, I hereby declare that:**

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SULFONAMIDE SUBSTITUTED BENZYLAMINE DERIVATIVES AND THEIR USE AS MEDICAMENTS

the specification of which  
☐ is attached hereto

OR

☒ was filed on  
(MM/DD/YYYY)

06/15/2000

as United States Application Number or PCT International

Application  
Number

PCT/GB00/02361

and was amended on  
(MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority sheet attached hereto:

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional applications(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
9916434.5	07/13/1999	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority sheet attached hereto.

**DECLARATION**

I hereby claim the benefit under Title 35, United States Code §120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
-----------------------------------	----------------------	------------------------------------	---

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority sheet attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

Attorney Name	Reg. No.
Arvie J. Anderson	45,263
Lynn D. Apelgren	45,341
Robert A. Armitage	27,437
Brian P. Barrett	39,697
Michael T. Beles	34,494
Roger S. Benjamin	27,025
Gary M. Birch	48,881
William R. Boudreaux	35,796
Steven P. Caltrider	36,467
Paul R. Cantrell	36,470
Charles E. Cohen	34,565
Donald L. Corneglio	30,741
Gregory A. Cox	47,504
Paul K. Davis	47,547
Elizabeth A. Dawalt	44,545
John C. Demeter	30,487
Marisha A. Desai	43,586
Joanne Longo Feeney	35,134
Poll J. Gaylo	36,908
Francis O. Ginh	44,712
Janet A. Gongola	48,436
Arfy E. Hamilton	33,894
Frederick D. Hunter	26,915
Thomas E. Jackson	33,064
Charles Joyner	30,466
Gerald P. Keleher	43,707

Attorney Name	Reg. No.
James J. Kelley	41,888
Paul J. Koivuniemi	31,533
Robert E. Lee	27,919
Kirby Lee	47,744
James P. Leeds	35,241
Nelsen L. Lentz	38,537
Douglas K. Norman	33,267
Arieen Palmberg	40,422
Thomas G. Plant	35,784
Edward Prein	37,212
Grant E. Reed	41,264
James J. Sales	33,773
Michael J. Sayles	32,285
Robert L. Sharp	45,609
David M. Stemerick	40,187
Mark J. Stewart	40,206
Robert D. Titus	45,466
Robert C. Tucker	47,145
Tina M. Tucker	36,711
MaChari Vorndran-Jones	43,972
Gilbert T. Voy	39,872
Thomas D. Webster	29,487
Lawrence T. Welch	45,782
Alexander Wilson	48,613
Dan L. Wood	

☐ Additional registered practitioner(s) named on a supplemental sheet attached hereto.

Direct all correspondence to:

Name **ELI LILLY AND COMPANY**  
 Address **ATTN: Janet A. Gongola**  
 Address **LILLY CORPORATE CENTER/DC1104**  
 City **INDIANAPOLIS** State **INDIANA** ZIP **46285**  
 Country **US** Telephone **(317) 277-6186** Fax **(317) 276-3861**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A Petition has been filed for this unsigned inventor

Given Name **Sandra** Middle Name **Ginette** Family Name **Milutinovic** Suffix **e.g. Jr.**  
 Inventor's Signature *Sandra Milutinovic* Date **3-DEC-2001**  
 Residence: City **Reading** State **Berkshire** Country **UK** Citizenship **FR**  
 Address **39 Devonshire Park,**  
 Post Office Address **SAME AS ABOVE**  
 City **Reading** State **Berkshire** Postal Code **RG2 7DX** Country **UK**

☒ Additional Inventors are being named on supplement sheet(s) attached hereto.



## DECLARATION

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	<u>Robin</u>	Middle Name	<u>George</u>	Family Name	<u>Simmonds</u>	Suffix e.g. Jr.	
Inventor's Signature	<i>Robin George Simmonds</i>				Date	<u>3/12/01</u>	
Residence: City	<u>Wokingham</u>	State	<u>Berkshire</u>	Country	<u>UK</u>	Citizenship	<u>UK</u>
Address		<u>2 Plover Close,</u>					
Post Office Address		<u>SAME AS ABOVE</u>					
City	<u>Wokingham</u>	State	<u>Berkshire</u>	Postal Code	<u>RG41 3JD</u>	Country	<u>UK</u>

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A Petition has been filed for this unsigned inventor			
Given Name	<u>David</u>	Middle Name	<u>Edward</u>	Family Name	<u>Tupper</u>	Suffix e.g. Jr.	
Inventor's Signature	<i>David Edward Tupper</i>				Date	<u>3/1/02</u>	
Residence: City	<u>Reading</u>	State	<u>Berkshire</u>	Country	<u>UK</u>	Citizenship	<u>UK</u>
Post Office Address		<u>8 Mildenhall Close, Lower Earley,</u>					
Post Office Address		<u>SAME AS ABOVE</u>					
City	<u>Reading</u>	State	<u>Berkshire</u>	Postal Code	<u>RG6 3AT</u>	Country	<u>UK</u>